Innovative Medicine
Pioneering breakthrough therapies across six core therapeutic
areas.
Oncology Leadership
J&J is a global leader in hematology
and is rapidly expanding its
footprint in solid tumors. The focus
is on curative pathways, utilizing
cell therapies (CAR-T) and bispecific
antibodies to target previously
untreatable cancers.
Flagship Assets:
DARZALEX,
CARVYKTI, and TECVAYLI continue
to redefine standards of care in
multiple myeloma.
Immunology &
Neuroscience
Maintaining a multi-decade
leadership in immunology, J&J is
transitioning toward next-
generation IL-23 inhibitors. In
Neuroscience, the focus remains on
mood disorders and
neurodegenerative diseases with
significant unmet needs.
Key Therapies:
TREMFYA,
STELARA, and SPRAVATO.
Therapeutic Portfolio Mapping
Relative Distribution of Pipeline Assets by Phase (Internal Projection)
3
